Business Context and Reporting Period
This Form 8-K Current Report was filed by Silo Pharma, Inc. on April 12, 2021. The filing discloses the entry into a material definitive agreement regarding a patent license and details unregistered sales of equity securities involving the forced conversion of preferred stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on corporate actions and equity structure changes rather than operational financial performance.
Material Changes
- Patent License Amendment: On April 12, 2021, the Company amended its Patent License Agreement with AIkido Pharma Inc. Under this amendment, AIkido delivered 500 shares of its Series M Convertible Preferred Stock to the Company, which converts into an aggregate of 625,000 shares of AIkido's common stock.
- Equity Conversion: Effective April 14, 2021, the Company forced the conversion of 4,048 shares of its Series C Convertible Preferred Stock into 13,495,014 shares of its common stock. This follows a February 2021 issuance of 4,276 shares of Series C stock and warrants to purchase up to 14,253,323 shares of common stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosures associated with the amendment of the patent license and the conversion of equity securities. The summary of the Amendment is qualified by reference to the full agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 (Amendment No. 1 to Patent License Agreement) for complete terms regarding the AIkido Pharma Inc. stock delivery.
- Verify the impact of the 13,495,014 newly issued common shares on existing shareholder dilution.
- Confirm the status of the remaining 228 shares of Series C Convertible Preferred Stock (4,276 issued minus 4,048 converted) and the associated warrants.